Quantum Surgical’s Epione Robot Gains Expanded Approval in Europe for Bone Tumors and Lesions

September 17, 2025—Quantum Surgical announced it has obtained CE Mark approval for the expanded use of its Epione robotic platform in the treatment of bone tumors and metastases. The platform can also be used for bone consolidation.

According to Quantum Surgical, the Epione robotic platform assists physicians in performing percutaneous tumor ablations, providing patients with a safe and effective alternative to surgery. It is designed to allow physicians to treat inoperable tumors that are particularly difficult to reach due to size or location at an early stage, noted the company.

With the new indication, Epione can now be used in percutaneous procedures (eg, bone consolidation in the pelvis and spine). The device was previously approved in Europe to treat tumors in the abdomen (including the liver, kidneys, and pancreas) and chest (lungs).

Epione is currently available in approximately 15 hospitals in Europe and the United States.

In March 2022, the company announced FDA 510(k) clearance for Epione to facilitate treatment of early stage liver disease.

The latest CE Mark approval was based on a clinical study conducted in three hospitals in France: Gustave Roussy in Villejuif, the Paoli-Calmettes Institute in Marseille, and the Hospices Civils de Lyon in Lyon.

Baptiste Bonnet, MD, an interventional radiologist at Gustave Roussy, commented on the milestone in the company’s press release.

“The clinical study conducted at Gustave Roussy has demonstrated the relevance of Epione in the practice of bone percutaneous procedures,” stated Dr. Roussy. “We will keep integrating robotics in these procedures which allow for better patient care.”